Dividend Win Wednesday: 37% ROIC Gold, Steel Insiders, and $7M Biogen Buys
Top 5 Pixie Picks
Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Dividend stocks.
Sign in →6. Merck & Co., Inc. (MRK)
Stock Pixie Score 7.0/10 | ROIC 25.3% | Earnings Yield 6.3% | Gross Margin 74.8%
Merck delivers a 25.3% ROIC, 6.3% earnings yield, and 74.8% gross margin. The 6.9% drawdown is minimal, and the normalized 10-year earnings yield of 1.9% is the highest on this screen, signaling durable profitability through patent cycles.
Revenue growth is just 1.3% year-over-year, reflecting the looming Keytruda patent cliff. Net debt/EBITDA of 1.24 is elevated for pharma, and the insider sentiment score of 4.94/10 reflects balanced activity with 19,199 net shares sold over six months (22.3% buys, 23.6% sells).
Merck announced a $6.7 billion acquisition of Terns to bolster its cancer portfolio pre-Keytruda expiration. WSJ and AP coverage framed the deal as a strategic hedge against the 2028 patent loss. No significant insider purchases in the past 30 days.
The Keytruda cliff is well-telegraphed, but execution risk on the Terns integration and pipeline development will determine whether the dividend grows or plateaus post-2028.
7. GSK plc (GSK)
Stock Pixie Score 6.9/10 | ROIC 26.3% | Earnings Yield 6.7% | Gross Margin 72.4%
GSK posts a 26.3% ROIC, 6.7% earnings yield, and 72.4% gross margin with a 10.1% drawdown. The normalized 10-year earnings yield of 2.3% is the strongest on this screen, reflecting consistent profitability through vaccine and specialty pharma cycles.
Analyst upside is modest at 3.6%, and revenue growth of 4.1% year-over-year is tepid for a company exiting legacy consumer health. Net debt/EBITDA of 1.27 and EV/EBITDA of 20.8× suggest limited margin for error if pipeline execution slips.
Scott Braunstein, Ashley Dombkowski, and Lori Lyons-Williams filed Form 4 transactions on Mar 5. Proactive Investors notes a court ruling lifted a vaccine-related legal cloud, and Zacks covered the orphan drug designation for Risvutatug Rezetecan in Japan lung cancer.
Insider activity over six months shows zero net share change, flagging neutral sentiment. The setup is yield and quality, not growth.
8. BlackRock, Inc. (BLK)
Stock Pixie Score 6.8/10 | Revenue Growth 18.7% | Analyst Upside 39.9% | Drawdown 22.6%
BlackRock is down 22.6% from its high, landing in "strong entry" territory with analysts targeting $1,320.94 (39.9% upside). Revenue grew 18.7% year-over-year, and the company disclosed its crypto business will generate $500 million in annual revenue.
The P/E of 26.7× is elevated for asset management, and the normalized 10-year earnings yield is negative 0.6%, reflecting the iShares acquisition and equity comp drag in the baseline. Interest coverage of 13.4× is solid, but net debt/EBITDA of 0.08 leaves little cushion if AUM flows reverse.
Stephen Cohen (Feb 25) and J. Richard Kushel (Feb 26) filed Form 4 purchases. Insiders added $5.21 million over six months with a 2:1 buy-to-sell ratio (8.5% buys, 4.2% sells). CEO Larry Fink warned of a "global recession" if oil hits $150, per BBC coverage via Reuters.
AUM is the revenue driver. If equity markets stall or crypto adoption slows, the $500 million crypto revenue story becomes a headwind, not a catalyst.
What to Watch
- Steel earnings revisions for Nucor and Steel Dynamics as Q1 results approach; pricing trends and infrastructure demand will dictate whether dividend growth accelerates or flattens.
- Gold price trajectory and geopolitical headlines tied to Newmont; peace talk volatility and dollar strength will move the stock more than fundamentals in the near term.
- Merck's Terns integration updates and pipeline readouts as the market prices in post-Keytruda revenue streams; any delay flags dividend risk.
- BlackRock AUM flows and crypto revenue disclosures in the next quarterly filing; the $500 million crypto figure needs line-item validation to support the 40% analyst upside case.
Go Deeper
The dividend screener ranks stocks by income quality, valuation, and price recovery signals, prioritizing sustainable payouts over high yields. What the top 8 don't show: payout cover ratios, FCF yield detail, and the full insider transaction ledger with dollar amounts and timing. Pro subscribers see those fields, plus 30+ additional metrics per ticker, updated daily.
Pro-only analytics
Named tickers from this article open in the app with Pro or an active trial.
Sign in →Stock Pixie Pro
See the full dividend screen — every pick, every metric, every day.
The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.
Start your free trial →